FOLEY HOAG LLP for GILEAD SCIENCES INC
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL KIM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.